🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Placebo for Benralizumab, Fasenra 30 mg solution for injection in pre-filled syringe, Symbicort forte Turbuhaler 320 microgramos/9 microgramos/inhalación polvo para inhalación., Symbicort Turbuhaler 160 microgramos/4,5 microgramos/inhalación polvo para inhalación

    AstraZeneca AB

    Eosinophilic Asthma

    phase 3 small molecule active

    1 trial

  2. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  3. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  4. Placebo for Capivasertib, PACLITAXEL, Capivasertib, Capivasertib

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  5. Placebo for Clarithomycin film-coated tablets (500mg), KLARICID® 500 mg επικαλυμμένα με λεπτό υμένιο δισκία

    The George Institute

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

  6. Placebo for Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  7. Placebo for Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation (FC)

    phase 3 small molecule completed

    1 trial

  8. Placebo for MK-0616, Placebo for Ezetimibe, EZETIMIBE , BEMPEDOIC ACID , MK-0616, Placebo for Bempedoic Acid

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  9. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  10. Placebo for Maridebart cafraglutide, AMG 133, AMG 133, AMG 133, AMG 133

    Amgen

    Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    phase 3 small molecule active

    1 trial

  11. Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection

    GlaxoSmithKline

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  12. Placebo for Mitapivat, MITAPIVAT

    Lacuna Pharma Pty Ltd

    Non–Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  13. Placebo for Nucresiran, ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  14. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand GmbH

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

  15. Placebo for PF-06651600-15, 50 mg, DEXAMETHASONE, Ritlecitinib tosilate, Placebo for PF-06651600-15, 100 mg, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    nonsegmental vitiligo

    phase 3 small molecule active

    1 trial

  16. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  17. Placebo for Ralinepag extended-release tablets, Ralinepag, Ralinepag, Ralinepag

    United Therapeutics Europe Ltd

    Pulmonary arterial hypertension (PAH)

    phase 3 small molecule active

    1 trial

  18. Placebo for Risankizumab Solution for Injection 90 mg/mL, Risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  19. Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  20. Placebo for efgartigimod, ARGX-113

    argenx

    Chronic Idiopathic thrombocytopenic purpura

    phase 3 small molecule active

    1 trial

  21. Placebo for efgartigimod, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  22. Placebo for empasiprubart- solution for IV infusion, ARGX-117

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  23. Placebo for fezolinetant film-coated tablets 45 mg, fezolinetant

    Astellas Pharma GmbH

    Moderate to Severe Vasomotor Symptoms (VMS)

    phase 3 small molecule active

    1 trial

  24. Placebo for glepaglutide, Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources